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A B S T R A C T
Objective: Chronic subdural hematoma (CSDH) is a condition that is frequently seen in the neurological and
neurosurgical practice. Surgical treatment is overall preferred; however, conservative treatment is also an op-
tion. Both surgical and conservative treatment of CSDH vary across neurosurgeons. The aim of the present study
was to evaluate different treatment strategies for CSDH among neurosurgeons in different countries.
Material and Methods: We designed a survey that was sent to neurosurgeons affiliated with the Congress of
Neurological Surgeons.The questions were related to the conservative and surgical treatment methods of CSDH.
Furthermore, we also included questions related to post-operative care.
Results: 443 neurosurgeons completed the survey. 46.2 % of the respondents sometimes use dexamethasone as
monotherapy. Overall, 26.2 % estimated dexamethasone to have a high efficacy on CSDH.
A Glasgow Coma Score lower than 12 was considered to be the most important indication for surgery by 57.8
%. Double burr hole is the preferred surgical technique by 48.1 % of the respondents. One day after surgery, 69.3
% routinely orders a CT-scan.
Conclusions: The majority of the neurosurgeons worldwide remains reluctant in the use of conservative treat-
ment methods in the management of CSDH. Further research is needed to assess the effectivity and side-effects of
these conservative methods.
1. Introduction
Chronic subdural hematoma (CSDH) is a condition that is frequently
seen in the neurological and neurosurgical practice. CSDH is most
commonly seen in the elderly population [2,6]. With the ageing po-
pulation there is an expected increase of CSDH worldwide, with an
incidence of 58 per 10,000 among people older than 65 [2]. The in-
cidence of CSDH in the general population is 5 per 10,000 [2,4].
Surgery by burr hole drainage is overall preferred in patients with
neurological symptoms [1,16]. It is noted that a minor part of the
neurosurgeons prescribe medical therapy, instead of or in addition to
surgery, for the treatment of CSDH [1]. Conservative treatment may
consist of prescription of ACE-inhibitors, corticosteroids, atorvastatin or
tranexamic acid. The effectiveness of these medications is expected due
to their anti-angiogenic, anti-inflammatory, or antifibrinolytic char-
acteristics, respectively [7,10–13,22].
With regard to the treatment protocols, practice variation is shown
by neurosurgeons, especially in the case of CSDH with mild neurolo-
gical deficits. Treatment of CSDH, both surgical and conservative,
varies across neurosurgeons [1,16,22]. Previous studies have shown
that conservative treatment is usually not part of their routine [1,6,16].
More specifically, due to the lack of high-class evidence and guidelines,
treatment with corticosteroids, ACE-inhibitors, tranexamic acid or
atorvastatin is not adapted among neurosurgeons. The aim of the pre-
sent study was to evaluate the use of different treatment strategies for
CSDH among neurosurgeons employed in countries worldwide.
2. Material and methods
2.1. Study design
A survey has been created with SurveyMonkey. Questions were
based on the literature and expert opinion [1,3,16,18].
The questionnaire contains twenty-one questions that can be
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divided into four sections:
1 Demographics of respondents
2 Frequency of surgical and conservative treatment methods used
(classified as usually, sometimes or never).
3 Expected effectiveness and complications of conservative treatment
(classified as highest, high, neutral, low or lowest).
4 Indication for surgery and surgical management (classified as most,
more, neutral, less or least).
5 Postsurgical management e.g. indications postoperative CT-scan and
timing of resumption of anticoagulants.
The member directory of the Congress of Neurological Surgeons
(CNS), an international organization for neurosurgeons worldwide, was
used to approach members. Retrievable email addresses of CNS mem-
bers were used to send the survey in September 2019, with reminders
after respectively two, four and six weeks to improve the response rate.
2.2. Statistical methods
Respondents’ data were collected and processed with Microsoft
Excel. For the quantitative and qualitative data analysis, software
program STATA was used for the quantitative and qualitative data
analysis. According to the type of data, a logistic regression was per-
formed to estimate causal effects of the variables. Statistical sig-
nificance was set at a 5% level.
3. Results
3.1. Demographics of respondents
The survey was completed by 443 neurosurgeons (response rate 7.3
%). Of all respondents, the majority was from North America (75.6 %)
whereas Australia (0.7 %) and Africa (1.4 %) had the least respondents
(Table 1, Fig. 1). The mean age of respondents was 50.5 years (± 13.4),
with an average time of neurosurgical practice of 24.3 years (± 16.0).
The substantial scope of practice of respondents was spinal surgery
(69.3 %), neuro-oncology (58.0 %) and neurotrauma (63.7 %). More
than 80 % of the respondents treated more than five patients with CSDH
per year.
3.2. Expected effectiveness and complications of conservative management
For conservative treatment of CSDH, dexamethasone was most fre-
quently used: 25 (7.4 %) respondents reported to prescribe it “usually”
and 157 (46.2 %) “sometimes” (Fig. 2). Other non-surgical options were
rarely applied; ACE-inhibitors, atorvastatin and tranexamic acid were
never prescribed by 92.0 %, 89.8 % and 78.7 % of the respondents,
respectively. Other nonsurgical treatment options applied by single
respondents were vitamin B or C, blood platelets or the Japanese herbal
medicine Goreisan.
The expected clinical features of atorvastatin, ACE-inhibitors, dex-
amethasone and tranexamic acid are shown in Fig. 3. Nineteen (5.6 %)
and 70 (20.6 %) respondents valued the expected effectiveness of
dexamethasone to be the high or highest, respectively. As for the other
treatment options, most respondents remained neutral towards the
expected effectiveness: 41.5 % of the respondents have mentioned to be
neutral about atorvastatin, 41.2 % about ACE-inhibitors and 51.6 %
about tranexamic acid respectively.
Expected complication risk was the lowest for atorvastatin: 84 (27.2
%) and 52 (16.8 %) respondents expect it to be low or lowest, respec-
tively (Fig. 3). Seventy-four (22.2 %) of the respondents expect the
complication risk of dexamethasone to be high. The majority of re-
spondents were neutral with regard to the expected recurrence risk of
atorvastatin (N= 187, 60.1 %), ACE-inhibitor (N=190, 61.3 %),
dexamethasone (N=173, 52.1 %) or tranexamic acid (N=190, 60.9
%).
3.3. Indication for surgery and surgical management
Respondents were asked what clinical aspects of CSDH were ex-
pected to be the most important to indicate surgery (Fig. 4). The most
important clinical indication for surgery is a Glasgow Coma Score (GCS)
lower than 12 (57.8 %), followed by a motor response of 5 or lower on
the GCS. The extent of the hematoma on the CT-scan is considered as
another important indication; 42.6 % as more important and 49.0 % as
most important indication, respectively.
Single burr hole and double burr holes were the techniques that
were applied mostly (30.4 % and 48.1 %, respectively) (Fig. 2). Of all
respondents, 95 (30.4 %) usually uses single burr hole and 150 (47.9 %)
of the respondents sometimes uses this technique. Double burr holes are
usually chosen for by 153 (48.1 %) respondents and sometimes used by
131 (41.2 %) respondents, followed by twist drill trephination, (usually
used by n=36, 11.6 % and sometimes by n= 87 28.2 %). Hemi-
craniotomy is never used by 134 (43.2 %) of the respondents. Fur-
thermore, other treatment options applied were middle meningeal ar-
tery embolization (by 8 respondents) and minicraniotomy (by 18
respondents).
As for the surgical procedures, double burr hole is seen as most
effective by most respondents (37.5 %) followed by hemicraniectomy
(29.8 %) and single burr hole (13.9 %) (Fig. 5). Twist drill trephination
was expected to have the lowest effectiveness. Hemicraniotomy and
double burr hole surgery were expected to have the lowest recurrence
risk (26.7 % and 13.5 % respectively). Of all respondents, 68.2 %
routinely left a drain; 57.6 % subdural while 10.6 % subperiosteal. This
in contrast to 7.5 %, that never leaves a drain. A logistic regression
analysis showed no causal relation between tenure and gender of the
surgeon, continent of employment or case load of CSDH treated and the
preferred surgical or conservative treatment strategy.
3.4. Postsurgical management
3.4.1. Post-operative CT scan
Of the respondents, 69.3 % usually orders a CT-scan one day after
surgical procedure (Fig. 6). With regard to resuming medication, 69.4
% and 59.6 % of the respondents orders a CT-scan before resuming oral
anticoagulants or antiplatelet therapy, respectively.
Table 1
Demographics of respondents.
Variable N (%) Variable N (%)
Age, mean (SD) 50.5
(± 13.4)
Patients with CSDH
seen yearly
N (%)
0 5 (1.13%)
Gender, N(%) 1 to 5 36 (8.1%)
Male 395 (89.2%) 6 to 10 82 (18.5%)
Female 48 (10.8%) 11 to 20 137 (30.9%)
More than 20 178 (40.2%)
Scope of practice N(%) Other 5 (1.13%)
Spine 307 (69.3%)
Neuro-oncology 257 (58.0%) Operative procedures
on CSDH yearly
N (%)
Pediatric 87 (19.6%) 0 6 (1.4%)
Neuro-vascular 154 (34.8%) 1 to 5 73 (16.5%)
Neurotrauma 282 (63.7%) 6 to 10 138 (31.2%)
Functional 52 (11.7%) 11 to 20 105 (23.7%)
Epilepsy 42 (9.5%) More than 20 118 (26.6%)
Peripheral 86 (19.4%) Other 3 (0.7%)
Skull Base 152 (34.3%)
Continent, N (%)
Time of practice,
mean (± SD)
24.3
(± 16.0)
North America 335 (75.6%)
South America 26 (5.9%)
Europe 33 (7.5%)
Asia 40 (9.0%)
Australia 3 (0.7%)
Africa 6 (1.4%)
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3.4.2. Resumption of antiplatelet and anticoagulant therapy
The resumption of antiplatelet or anticoagulant therapy one or two
weeks after surgery is advised by respectively 107 (32.5 %) and 94
(28.8 %) of the respondents (Fig. 7). Twenty-two (5.0 %) of the re-
spondents will allow resumption of anticoagulants and 6.7 % resump-
tion of oral antiplatelet therapy within 1 week after surgery. Based on a
postoperative CT scan 25.2 % of the respondents advises resumption of
antiplatelet therapy and 32.1 % of oral anticoagulants.
4. Discussion
The aim of this international survey was to explore currently ap-
plied treatment strategies of CSDH. Among 443 neurosurgeons of which
the majority treated more than five patients with CSDH yearly, con-
servative treatment methods such as atorvastatin, ACE-inhibitors and
tranexamic acid were almost never used in practice. Sometimes dex-
amethasone was used by almost half of the respondents. Single and
double burr hole surgery were the preferred surgical treatment options
among neurosurgeons. Twist drill trephination and hemicraniotomy
were infrequently used treatment options.
4.1. Comparison with other studies
The use of steroids in the treatment of CSDH has recently gained
popularity as a treatment alternative [13]. Our survey shows that 46.6
% of the neurosurgeons sometimes used dexamethasone as a mono-
therapy. Miah et al. conducted a study to compare the clinical outcomes
of patients with CSDH treated with dexamethasone as monotherapy
versus primary surgical management [13]. They found similar clinical
outcomes regarding to the modified Rankin Scale and Markwalder
Grading Scale in patients treated with dexamethasone versus surgical
management. At three months, 70 % of the patients in the group who
received primary burr hole surgery had a favorable score on the mod-
ified Rankin Scale (0–3) versus 76 % of the patients who received
dexamethasone initially. Furthermore, 96 % of both groups had a fa-
vorable score on the Markwalder Grading Scale (0–1). However, only
17 % of the patients treated with dexamethasone eventually did not had
to undergo surgery. This “conservative first” treatment strategy,
Fig. 1. Graphical overview of the respondents working locations.
Fig. 2. Graphical overview of the surgical and nonsurgical treatment methods applied.
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however, resulted into longer hospitalization and a higher complication
rate than primary burr hole surgery. Another retrospective study con-
cluded that the use of dexamethasone after burr hole trephination
reduces disease recurrence and complication risk [15,20]. The use of
dexamethasone in the treatment of CSDH is currently subject of large
randomized controlled trials of which the results are highly anticipated
Fig. 3. Graphical overview of the clinical expectations of nonsurgical treatment methods.
Fig. 4. Graphical overview of the indications for surgery.
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[4,14]
Atorvastatin is a conservative treatment method that is also ex-
pected to suppress inflammation at the site of the hematoma. Studies
have also shown that atorvastatin elevates angiogenin levels and in-
creases the expression of vascular endothelial growth factor [22]. The
inflammation subsequent to the subdural hemorrhage has been sus-
pected to disrupt the endothelial barrier cells, resulting in blood vessels
that ‘leak’. Through this mechanism, atorvastatin could be of merit in
the management of patients with CSDH, reducing the hematoma, re-
covering neurological function and decreasing the need for surgery
[10]. In our survey, most surgeons are reluctant to use atorvastatin as
monotherapy as 89.9 % never uses it. A recent randomized controlled
trial in which patients with CSDH were randomized between atorvas-
tatin and placebo, showed that patients who received atorvastatin had a
significantly more reduced hematoma as measured on CT-imaging and
had improved more neurologically as compared to patients who
Fig. 5. Graphical overview of the clinical expectations of surgical treatment methods.
Fig. 6. Graphical overview with indications for a postoperative CT-scan.
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received placebo [10]. Also, in a pooled meta-analysis of 6 studies, the
use of atorvastatin resulted in a decrease of recurrent CSDH requiring
surgery [7]. Therefore, the use of atorvastatin could be an effective
addition to the treatment of CSDH with and without surgery.
Tranexamic acid is a drug that has an antifibrinolytic and anti-in-
flammatory effect. It inactivates plasminogen. Therefore, it was hy-
pothesized by Kageyama et al. that it inhibits hyperfybrinolytic activity
that occurs at the site of a CSDH [11]. It is also thought to increase the
permeability of cerebral vessels, thus increasing absorption of the he-
matoma [21]. In the retrospective study of Kageyama et al., 21 patients
received tranexamic acid in the treatment of CSDH. Three of these
patients received tranexamic acid concomitant to burr hole surgery.
The other 18 patients received tranexamic acid as monotreatment. No
adverse events occurred, including thromboembolic events. All patients
in this study improved clinically while being treated with tranexamic
acid. All patients were seen as cured and had no recurrence of their
hematoma, underlining the clinical potency of tranexamic acid as a
treatment option. In our study, tranexamic acid rarely had a place in the
treatment of CSDH as 78.7 % of the surgeons never prescribe it.
A frequent adverse event after drainage of CSDH is recurrence of the
hematoma. In the literature, recurrence rates of up to 30 % can be
found [23]. Placing a subdural drain after hematoma evacuation has
been shown to reduce the risk of recurrence by two to three times as
compared to not placing a drain. Even on the long-term, placing a
subdural drain after evacuation of CSDH is associated with improved
survival. In our study, placement of drains was adopted by 68.2 % of
the respondents. 7.5 % of the respondents stated to not leave a drain
usually despite shown advantages.
The location of leaving the drain has been controversial [18]. In our
study sample there was a clear favoritism for placing the drain subdural
versus subperiosteal (57.6 % versus 10.6 %). Recently, results of a
multicenter randomized controlled trial comparing subperiosteal versus
subdural drain after evacuation of CSDH were published [19]. In that
study, 220 patients were randomized to one of both drain strategies
with the primary endpoint set on recurrence of CSDH requiring re-
operation. Even though the predefined non-inferiority criteria were not
met, placement of a subperiosteal drain led to lower recurrence rates
and significantly lower surgical infections and drain misplacements.
Together with nine other studies, of which two randomized studies, the
results of this trial were pooled in a recently published meta-analysis
[5]. The meta-analysis enforces the conclusion that subperiosteal
drainage is associated with less recurrence of CSDH and lower rates of
parenchymal injury of neurological deficit. The pooled results however,
showed that rates of mortality, seizures, postoperative hemorrhage and
infections were similar. Since two out of three randomized studies have
only been published in recent years, we hypothesize that the im-
plementation of subperiosteal drainage is expected in the coming
period.
In this study sample, 69.3 % of the neurosurgeons ordered a routine
postoperative CT-scan, one day after surgery. The value of these routine
CT-scans has been the focus of discussion throughout the years. A re-
cent study compared two neurosurgical centers with different policies;
one frequently ordered routine postoperative CT-scans while the other
only ordered CT-scans postoperatively if there was any neurological
decline [8]. Postoperatively, patients of the first center underwent a
median of 4 scans while patients at the latter underwent a median of 0
scans. Despite this difference in postoperative scans, there were no
significant differences between both centers in number of reinterven-
tions, while all re-interventions were preceded by neurological decline.
In a single-center randomized controlled trial, Schucht et al. found no
benefit in a routine CT-scan at 2 and 30 days postoperatively as com-
pared to a CT-scan only by indication in regards to 6 month survival
without severe disability (0–3 on modified Rankin scale) [17]. The
latter group also underwent fewer repeat surgeries.
Other studies have reported comparable outcomes as this study. A
survey held among Iranian neurosurgeons showed a strong preference
for treating CSDH with a single burr hole with drain placement [9]. This
procedure was applied in 64 % of the cases. Baschera et al. reported a
slightly different conservative treatment pattern. Results from a survey
among neurosurgeons in Austria, Germany and Switzerland showed
that 45 % of the respondents at least once prescribed tranexamic acid
[3]. In our study, tranexamic acid was used infrequently as 78.7 % of
our respondents answered to never prescribe tranexamic acid. The
strong favoritism for placing a drain subdural (which is the preference
of 90 % of the respondents) in Baschera et al. is in line with the results
from our study. In the same study, only 13 % of the respondents would
not postoperatively order a routine CT-scan.
As only a proportion of 7.3 % completed the survey, the question
raises if the results are representative. However, the absolute number of
responses, 443 responses, is still higher than in other surveys conducted
in this field so far. We assumed that the choice of completing a survey
does not interact with management strategies of CSDH. Another lim-
itation is that the strategy of watchful waiting has not been included in
this study as a treatment option. Furthermore, embolization of the
middle meningeal artery was not included in this survey as a treatment
option as this procedure is often done by intervention radiologists in
some countries, while this survey was more focused on neurosurgeons.
However, neurosurgeons had the opportunity to give additional an-
swers as an open-end response. As this study sample only included
neurosurgeons, the treatment variation might differ in practice. CSDH is
not only treated by neurosurgeons, but also neurologists. We assume
that compared to neurologists, neurosurgeons tempt to be more biased
concerning the conservative treatment methods. Therefore, these re-
sults might not reflect the treatment variation fully in practice.
5. Conclusion
Neurosurgeons remain reluctant in the use of conservative therapy
in the treatment of CSDH. This might be due to the lack of evidence-
based information and guidelines. However, studies have shown that
several treatment options could play an important role in the man-
agement of patients with CSDH due to their anti-inflammatory and anti-
fibrinolytic characteristics. These treatments could be administered in
combination with surgery or as monotherapy. Further research is ne-
cessary to assess the effectivity and side-effects of these particular
medicines. Furthermore, evidence-based guidelines need to be com-
posed for the conservative management of CSDH. In order to do so, the
pathophysiology of CSDH needs to be further studied.
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